RxDoctor Payments Data

Nadine Clarke, NP

Psychiatric/Mental Health · West Palm Beach, FLNPI 1366740979

Payments from drug & device makers

$898in general payments, 2019–2025

Across 28 payments — averaging $32.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$204
  • Neurocrine Biosciences, Inc.$153
  • Novo Nordisk$149
  • Alkermes, Inc.$100
  • Axsome Therapeutics, Inc.$83
  • Vanda Pharmaceuticals Inc.$58
  • plus $151 from 5 others

What the payments were for

  • Food & beverage$898100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$898 in reported general payments places this provider in the 55th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$10,662
Medicare patients
80
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$20,733
EliquisApixaban19$19,367
Lagevrio (Eua)Molnupiravir11$2,836
Albuterol Sulfate HfaAlbuterol Sulfate44$1,231
Rosuvastatin Calcium57$625
Metoprolol Succinate26$578
Atorvastatin Calcium70$568
Levothyroxine Sodium42$401
Alendronate Sodium37$367
Amlodipine Besylate67$299
Gabapentin19$275
Losartan Potassium43$267
Omeprazole22$211
Metformin Hcl48$209
Vitamin D2Ergocalciferol (Vitamin D2)25$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$149$20,73318 claims
PfizerEliquis$12$19,36719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →